224 related articles for article (PubMed ID: 15096959)
1. A rational approach for the treatment of acute heart failure: current strategies and future options.
Sharma M; Teerlink JR
Curr Opin Cardiol; 2004 May; 19(3):254-63. PubMed ID: 15096959
[TBL] [Abstract][Full Text] [Related]
2. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
3. Increased cost effectiveness with nesiritide vs. milrinone or dobutamine in the treatment of acute decompensated heart failure.
Scroggins N; Edwards M; Delgado R
Congest Heart Fail; 2005; 11(6):311-4. PubMed ID: 16330906
[TBL] [Abstract][Full Text] [Related]
4. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
Wang XC; Zhu DM; Shan YX
Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
[TBL] [Abstract][Full Text] [Related]
5. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
[TBL] [Abstract][Full Text] [Related]
6. Overview of randomized clinical trials in acute heart failure syndromes.
Teerlink JR
Am J Cardiol; 2005 Sep; 96(6A):59G-67G. PubMed ID: 16181824
[TBL] [Abstract][Full Text] [Related]
7. Treatment options for acute decompensated heart failure.
Southworth MR
Am J Health Syst Pharm; 2003 Aug; 60 Suppl 4():S7-15. PubMed ID: 12966901
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
9. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure.
Lewis DA; Gurram NR; Abraham WT; Akers WS
Am J Health Syst Pharm; 2003 Aug; 60 Suppl 4():S16-20. PubMed ID: 12966902
[TBL] [Abstract][Full Text] [Related]
10. The use of vasoactive therapy for acute decompensated heart failure: hemodynamic and renal considerations.
Heywood JT; Khan TA
Rev Cardiovasc Med; 2007; 8 Suppl 5():S22-9. PubMed ID: 18192950
[TBL] [Abstract][Full Text] [Related]
11. Nesiritide: a review of its use in acute decompensated heart failure.
Keating GM; Goa KL
Drugs; 2003; 63(1):47-70. PubMed ID: 12487622
[TBL] [Abstract][Full Text] [Related]
12. Acute decompensated heart failure: the shrinking role of inotropic therapy.
Dec GW
J Am Coll Cardiol; 2005 Jul; 46(1):65-7. PubMed ID: 15992637
[No Abstract] [Full Text] [Related]
13. B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure.
Fonarow GC
Heart Fail Rev; 2003 Oct; 8(4):321-5. PubMed ID: 14574051
[TBL] [Abstract][Full Text] [Related]
14. Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure.
King JB; Shah RU; Sainski-Nguyen A; Biskupiak J; Munger MA; Bress AP
Pharmacotherapy; 2017 Jun; 37(6):662-672. PubMed ID: 28475215
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
Saltzberg MT
Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
18. Newer approaches to the pharmacological management of heart failure.
Rauch H; Motsch J; Böttiger BW
Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
[TBL] [Abstract][Full Text] [Related]
19. Optimizing outcomes in the patient with acute decompensated heart failure.
Mehra MR
Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
[TBL] [Abstract][Full Text] [Related]
20. Acute decompensated heart failure and the cardiorenal syndrome.
Liang KV; Williams AW; Greene EL; Redfield MM
Crit Care Med; 2008 Jan; 36(1 Suppl):S75-88. PubMed ID: 18158481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
